Pocalciuric hypercalcemia (by family history) Other NOS Hypertriglyceridemia Hypertriglyceridemic risk (Fasting .300 mg/dL; non-fasting .500 mg/dL) Hypertriglyceridemic acute pancreatitis, history of (.500 mg/dL in 1st 72 hours) Familial hypertriglyceridemia (by family members history) Drugs NOS Toxins Chronic kidney disease (CKD) (CKD Stage five: end-stage renal disease, ESRD) No dialysis On dialysis Kidney transplant Oxidative anxiety ssociated components Radiation/chemotherapy Vascular insufficiency Other variables Other toxins, NOS Metabolic, other Diabetes Mellitus (together with the date of diagnosis if out there) Diet plan controlled Medication controlled (oral agents) Insulin requiring ( ten U/d or 0.1 U/kg/d) Diet plan (red meat 2 oz or 57 g per day; vegetarian, vegan) Obesity (BMI .30 kg/m2) Visceral adiposity (e.g., apple-shaped obesity, see text) Other, NOS Idiopathic Early onset (,35 years of age) Late onset (.35 years of age) Other, NOSLIST 1. TIGAR-O VERSION_V1 (ETEMAD AND WHITCOMB, 2001 (5))Toxic-metabolicAlcoholic BzATP (triethylammonium salt) Epigenetics Tobacco smoking Hypercalcemia Hyperparathyroidism Hyperlipidemia (uncommon and controversial) Chronic renal failure Drugs Phenacetin abuse (possibly from chronic renal insufficiency) Toxins Organotin compounds (e.g., DBTC)IdiopathicEarly onset Late onset Tropical Tropical calcific pancreatitis Respiratory Inhibitors targets Fibrocalculous pancreatic diabetes OtherGeneticAutosomal dominant Cationic trypsinogen (Codon 29 and 122 mutations) Autosomal recessive/modifier genes CFTR mutations SPINK1 mutations Cationic trypsinogen (codon 16, 22, 23 mutations) a1-Antitrypsin deficiency (feasible)AutoimmuneIsolated autoimmune chronic pancreatitis Syndromic autoimmune chronic pancreatitis ?Sjogren syndrome ssociated chronic pancreatitis Inflammatory bowel disease ssociated chronic pancreatitis Main biliary cirrhosis ssociated chronic pancreatitisRecurrent and extreme acute pancreatitisPostnecrotic (serious acute pancreatitis) Recurrent acute pancreatitis Vascular diseases/ischemic Post-irradiationObstructivePancreatic divisum Sphincter of Oddi disorders (controversial) Duct obstruction (e.g., tumor) Preampullary duodenal wall cysts Posttraumatic pancreatic duct scarsGeneticSuspected; No or limited genotyping readily available Autosomal dominant (Mendelian inheritance–single gene syndrome) PRSS1 mutations (Hereditary pancreatitis)Clinical and Translational GastroenterologyVOLUME 10 JUNE 2019 www.clintranslgastro.comTIGAR-O Version 2 Risk/Etiology ChecklisteCEL–MODY8 phenotype Other, NOS Autosomal recessive (Mendelian inheritance–single gene syndrome) CFTR, 2 severe variants in trans (cystic fibrosis) CFTR, ,two severe variants in trans (CFTR-RD) SPINK1, 2 pathogenic variants in trans. (SPINK1-associated familial pancreatitis) Other, NOS Complex genetics–(non-Mendelian, complex genotypes 1/2 atmosphere) CFTR variant (1 variant or .1 all in cis) CTRC variants CASR variants SPINK1 variant (1 variant or .1 all in cis) CPA1 variants CEL or CEL-HYB variants Other, NOS Modifier genes (pathogenic genetic variants) PRSS1-PRSS1 locus CLDN2 locus SLC26A9 GGT1 ABO–B blood variety Other, NOS Hypertriglyceridemia syndromes (pathogenic genetic variants) LPL–lipoprotein lipase deficiency APOC2–Apolipoprotein C-II deficiency Other familial chylomicronemia syndrome (FCS) Multifactorial chylomicronemia syndrome (MCS) Other, NOS Uncommon, non-neoplastic pancreatic genetic variant-associated syndromes Shwachman-Diamond syndrome Johanson-Blizzard Syndrome Mitochondrial problems (e.g., Pearson’s Marrow-Pan.
